No approved hantavirus vaccine exists, and the market’s 91.5% implied probability for “No” in 2026 reflects the absence of any candidate that has advanced beyond early clinical or preclinical stages. Multiple DNA and mRNA candidates, including those targeting Andes and Hantaan strains, have demonstrated neutralizing antibodies in animal models and limited Phase 1 human testing, yet none have entered pivotal efficacy trials. Regulatory approval typically requires completed Phase 3 data, which current pipelines lack and cannot realistically generate before year-end without an unprecedented acceleration program comparable to Operation Warp Speed. Ongoing preclinical work by groups such as Moderna–Korea University and independent virologists continues, but historical timelines for similar neglected pathogens indicate approval remains years away.